MABs

Question 1

Eculizumab

Answer 1

C5 complement
- treat atypical HUS
- RA
- SLE

Question 2

Omalizumab

Answer 2

IgE

Question 3

Mepalizumab

Answer 3

IL5

Question 4

Tocilizumab

Answer 4

IL6

Question 5

Adalimumab/Infliximab

Answer 5

TNF Alfa
- Crohns/IBD
- RA
- Psoriasis

Question 6

Rituximab

Answer 6

CD20
- Haemolytic anemia
- B cell malignancy
- Nephrotic syndrome

Question 7

Blinatumomab

Answer 7

CD3/CD19

Question 8

Dinutuximab

Answer 8

GD2 (neuroblastoma)

Question 9

Basilimab

Answer 9

IL2
Prevent GVHD/graft rejection

Question 10

Ocrelizumab

Answer 10

Anti CD20 (MS)

Question 11

Dupilumab

Answer 11

Anti IL4/13
(eczema, asthma, sinusitis)

Question 12

Cendakimab

Answer 12

anti IL 13

Question 13

Benralizumab

Answer 13

Anti IL5

Question 14

Imatinib

Answer 14

Tyrosine kinase inhibitor (used in Rx of ALL)

Question 15

Abatacept

Answer 15

Anti CD80/86 (T-cell signalling)

Question 16

Etanercept/adalimumab

Answer 16

Anti- TNF

Question 17

Dasatinib/imatinib/nilotinib

Answer 17

bCR-ABL – CML, Philadelphia chromosome +ve ALL

Question 18

Blinatumomab BiTE molecule – bispecific T cell engager

Answer 18

BiTE molecule – bispecific T cell engager
- binds CD19 positive cells (B cells) at one end and T cells at the other

Question 19

Trastuzumab

Answer 19

ERBB2/HER-2:
- BRCA

Question 20

Gefitinib, Erlotinib

Answer 20

EGFR
-NSCLC